Therapy News and Research

RSS

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Study finds Gamma Knife procedure effective for brain metastases treatment

The volume of normal brain tissue exposed to radiation during treatment for multiple metastases appears to depend on which stereotactic radiosurgery system is employed, according to a recent study in the Journal of Neurosurgery.

31 Mar 2011

Scientia Vascular's PLATO microcatheters granted CE mark

Scientia Vascular, developer of innovative products that are optimized for endovascular access and therapies, announced today that its PLATOTM Microcath has received CE Mark approval, facilitating availability for European neuro, cardio and peripheral endovascular applications.

31 Mar 2011

Positive outcomes from imatinib trial in both older and younger patients with CML

While the median age at diagnosis for chronic myeloid leukemia is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.

31 Mar 2011

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

Boceprevir drug can help cure hard-to-treat hepatitis C

The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study's findings.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

Immunotec, NSU to conduct new research study in children with autism

Nova Southeastern University and the dietary supplement company Immunotec announced today that they will conduct a new research study to determine the effects of a supplement to improve behaviors in children with Autism Spectrum Disorder.

31 Mar 2011

3D experiments reveal MSCs have potential to produce different cell types

A type of adult stem cell is now proving itself more versatile for research and therapies thanks to revolutionary 3D experiments. These cells have already shown great promise for repairing damaged bone and cartilage but until now have been fairly limited in the types of cells they can form in the laboratory.

31 Mar 2011

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

Abbott launches MitraClip system to treat MR in Australia

Abbott today announced the launch of the company's catheter-based MitraClip system for the treatment of mitral regurgitation in Australia. The MitraClip device, which has received Therapeutic Goods Administration approval, offers a new treatment option for patients suffering from MR, a debilitating heart valve condition.

31 Mar 2011

Could HIV-infected organs save 'lives?

Johns Hopkins researchers argue for reversing ban on transplanting infected organs and making them available to HIV-infected patients

30 Mar 2011

Radiation oncologists head to Capitol Hill to promote critical initiatives

More than 100 radiation oncology treatment team members and resident physicians convened in Washington Monday and Tuesday to represent radiation oncology on Capitol Hill at the American Society for Radiation Oncology's (ASTRO) eighth annual Advocacy Day. Participants spent Monday hearing from members of Congress and key congressional staff on the latest legislative activity and ASTRO'’s legislative agenda. On Tuesday, the group headed to House and Senate office buildings to meet with senators, congressmen and staffers from their home states to promote agenda items important to the safety and well-being of cancer patients.

30 Mar 2011

Allscripts ED 7.0 receives Complete EHR certification

Allscripts announced today that Allscripts ED™ 7.0, the company's standalone Emergency Department Information System (EDIS), is 2011/2012 compliant and was certified as a Complete EHR on March 2, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable hospital certification criteria adopted by the Secretary of Health and Human Services.

30 Mar 2011

Singing reduces blood pressure prior to total knee replacement surgery

Doctors report that singing reduced the blood pressure of a 76-year-old woman who had experienced severe preoperative hypertension prior to total knee replacement surgery for osteoarthritis (OA). While the patient was unresponsive to aggressive pharmacologic interventions, the woman's blood pressure dropped dramatically when she sang several religious songs.

30 Mar 2011

XTRAC laser therapy can offer relief to patients with severe psoriasis

PhotoMedex, Inc. announced today the implications of the preliminary findings of a current clinical trial being performed by John Y.M. Koo, M.D., professor and vice chairman, department of dermatology, University of California, San Francisco. Dr. Koo's experimental treatment protocol could change the lives of millions of people suffering from moderate to severe psoriasis.

30 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

New stereo-EEG method can detect epileptic foci during surgeries

The neurosurgery department of HUCH has started to utilize stereo-EEG method for localizing the epileptic focus in severe epilepsy for epilepsy surgery purposes. The department is also getting ready to introduce the so-called deep brain stimulation therapy in the treatment of epilepsy.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011